Regeneron’s Fianlimab Misses Primary Endpoint in Melanoma Trial
Regeneron's fianlimab melanoma trial missed its primary endpoint for progression-free survival, though the high-dose combination showed a 5.1-month numerical...
SN BioScience Begins Phase 1b/2 Trial of SNB-101 for Small Cell Lung Cancer
SN BioScience begins Phase 1b/2 trial of SNB-101, a nanoparticle SN-38 formulation, in extensive-stage small cell lung cancer patients...
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD
EyePoint's DURAVYU receives third consecutive positive safety review in wet AMD Phase 3 trials, with over 900 randomized patients...
Envudeucitinib Shows 68% PASI 90 Response in Phase 3 Psoriasis Trials
Envudeucitinib achieves 68% PASI 90 response in Phase 3 psoriasis trials, surpassing current oral therapy benchmarks at Week 24.
Cardiff Oncology Advances Onvansertib to Phase 3 for RAS-Mutated Colorectal Cancer
Cardiff Oncology advances onvansertib Phase 3 for RAS-mutated colorectal cancer after 72.2% response rate in Phase 2 trial.
Biogen’s Diranersen Shows Tau Biomarker Reduction in Phase 2 Alzheimer’s Study
Biogen's diranersen shows tau biomarker reduction in Phase 2 Alzheimer's study, signaling potential for combination therapy approaches despite missing...
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML
Senti Biosciences gains FDA backing for SENTI-202 donor selection strategy in relapsed/refractory AML, with 50% complete remission rates tied...
ZUSDURI Shows 64.5% Disease-Free Rate at 36 Months in Bladder Cancer Trial
ZUSDURI demonstrates 64.5% disease-free rate at 36 months in bladder cancer trial, offering durability without maintenance therapy for recurrent...
Upstream Bio Caps COPD Study, Redirects to Phase 3 Design
Upstream Bio caps COPD Study enrollment at 400 participants and pivots to Phase 3 design around quarterly dosing for...
Voyager’s VY1706 cuts tau 64% in primates with no safety issues
Voyager's VY1706 achieves 64% tau reduction in primates with no safety issues, clearing preclinical path for human trials later...